Key facts
- This page summarizes Sharon Benzeno's Form 4 filing for Adaptive Biotechnologies Corp (ADPT).
- 12 reported transactions and 5 derivative rows are listed below.
- Accepted by SEC: 30 Jun 2026, 19:25.
Sharon Benzeno - 26 Jun 2026 Form 4 Insider Report for Adaptive Biotechnologies Corp (ADPT)
- Reporting relationship
- Chief Commercial Ofc Imm Med
- Issuer ticker
- ADPT
- Reported as of
- 26 Jun 2026
- Net transaction value
- -$3,503,510
- SEC form
- 4
- Accepted by SEC
- 30 Jun 2026, 19:25:11 UTC
- Prior SEC filing
- 13 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- /s/ Sharon Benzeno by Kyle Piskel, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Sharon Benzeno filed Form 4 for Adaptive Biotechnologies Corp (ADPT) on 30 Jun 2026.
Change
- Previous filing in this sequence was filed on 13 Mar 2026.
- Current net transaction value: -$3,503,510.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001780854
Primary reporting owner
BENZENO SHARON
- Relationship
- Chief Commercial Ofc Imm Med
- Address
- C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVENUE EAST, SEATTLE
- Signature
- /s/ Sharon Benzeno by Kyle Piskel, Attorney-in-Fact
- Signature date
- 30 Jun 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ADPT
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +11,034
- Change %
- +4%
- Price
- $12.14*
- Shares after
- 283,785
- Date
- 26 Jun 2026
- Ownership
- Direct
- Footnotes
- F1
ADPT
transaction
Common Stock
Sale
- Transaction value
- $231,714
- Shares
- -11,034
- Change %
- -3.9%
- Price
- $21.00
- Shares after
- 272,751
- Date
- 26 Jun 2026
- Ownership
- Direct
- Footnotes
- F1, F2
ADPT
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +1,837
- Change %
- +0.67%
- Price
- $12.14*
- Shares after
- 274,588
- Date
- 29 Jun 2026
- Ownership
- Direct
- Footnotes
- F1
ADPT
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +24,944
- Change %
- +9.1%
- Price
- $8.46*
- Shares after
- 299,532
- Date
- 29 Jun 2026
- Ownership
- Direct
- Footnotes
- F1
ADPT
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +24,944
- Change %
- +8.3%
- Price
- $3.99*
- Shares after
- 324,476
- Date
- 29 Jun 2026
- Ownership
- Direct
- Footnotes
- F1
ADPT
transaction
Common Stock
Options Exercise
- Transaction value
- Shares
- +51,570
- Change %
- +16%
- Price
- $8.12*
- Shares after
- 376,046
- Date
- 29 Jun 2026
- Ownership
- Direct
- Footnotes
- F1
ADPT
transaction
Common Stock
Sale
- Transaction value
- $3,271,796
- Shares
- -154,768
- Change %
- -41%
- Price
- $21.14
- Shares after
- 221,278
- Date
- 29 Jun 2026
- Ownership
- Direct
- Footnotes
- F1, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ADPT
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- Shares
- -11,034
- Change %
- -86%
- Price
- $0.000000*
- Shares after
- 1,837
- Date
- 26 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 11,034
- Exercise price
- $12.14
- Footnotes
- F1, F4
ADPT
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- Shares
- -1,837
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 29 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 1,837
- Exercise price
- $12.14
- Footnotes
- F1, F4
ADPT
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- Shares
- -24,944
- Change %
- -40%
- Price
- $0.000000*
- Shares after
- 37,416
- Date
- 29 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 24,944
- Exercise price
- $8.46
- Footnotes
- F1, F5
ADPT
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- Shares
- -24,944
- Change %
- -22%
- Price
- $0.000000*
- Shares after
- 87,303
- Date
- 29 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 24,944
- Exercise price
- $3.99
- Footnotes
- F1, F6
ADPT
transaction
Derivative
Stock Option (right to buy)
Options Exercise
- Transaction value
- Shares
- -51,570
- Change %
- -31%
- Price
- $0.000000*
- Shares after
- 113,457
- Date
- 29 Jun 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 51,570
- Exercise price
- $8.12
- Footnotes
- F1, F7
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 7 footnotes
Footnote F1
The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2025.
Footnote F2
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.00 to $21.01, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Footnote F3
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $21.00 to $21.38, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
Footnote F4
The option was fully vested and exercisable.
Footnote F5
The options vested with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Footnote F6
The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
Footnote F7
The options vested with respect to 1/4 of such shares on March 4, 2026, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.